A phase II study of docetaxel plus nedaplatin in patients with metastatic non-small-cell lung cancer
Purpose Nedaplatin is a cisplatin derivative, which has similar activity to cisplatin in non-small-cell lung cancer (NSCLC) when combined with vindesine, and causes less nausea/vomiting and nephrotoxicity compared with cisplatin. The aim of this study was to evaluate the efficacy and safety of combi...
Gespeichert in:
| Veröffentlicht in: | Cancer chemotherapy and pharmacology 2012-10, Vol.70 (4), p.531-537 |
|---|---|
| Hauptverfasser: | , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 537 |
|---|---|
| container_issue | 4 |
| container_start_page | 531 |
| container_title | Cancer chemotherapy and pharmacology |
| container_volume | 70 |
| creator | Teramoto, Koji Asada, Yoshikuni Ozaki, Yoshitomo Suzumura, Yuji Nakano, Yasutaka Sawai, Satoru Tezuka, Noriaki Inoue, Shuhei Fujino, Shozo |
| description | Purpose
Nedaplatin is a cisplatin derivative, which has similar activity to cisplatin in non-small-cell lung cancer (NSCLC) when combined with vindesine, and causes less nausea/vomiting and nephrotoxicity compared with cisplatin. The aim of this study was to evaluate the efficacy and safety of combination chemotherapy with docetaxel plus nedaplatin in patients with metastatic NSCLC.
Methods
Patients with metastatic stage IIIB excluding locally advanced diseases or stage IV NSCLC were enrolled between March 2004 and March 2006. They were treated with docetaxel (60 mg/m
2
) and nedaplatin (80 mg/m
2
) on day 1 every 3–4 weeks until progression or intolerable toxicity for up to 4 cycles.
Results
Forty-four patients (mean age, 65 years; range, 40–79 years) received a total of 140 treatment cycles. Responses could be assessed in all patients (complete response, 0; partial response, 22; stable disease, 11; and progressive disease, 11). Response rate was 50.0 % (95 % confidence interval [CI], 35.2–64.8 %) with a disease control rate of 75.0 % (95 % CI, 62.2–87.8 %). A high response rate was achieved in patients with squamous cell carcinoma (66.7 %) compared with that in patients with adenocarcinoma (41.4 %). Median survival time from the start of the combination chemotherapy was 13.0 months, and the progression-free survival time was 7.4 months. Grade 3 or 4 hematologic toxicities included leukopenia (28.6 %) and neutropenia (61.4 %). Nonhematologic toxicities were mild.
Conclusion
The combination of docetaxel plus nedaplatin was well tolerated and demonstrated potent activity in patients with metastatic NSCLC, particularly squamous cell carcinoma of the lung. |
| doi_str_mv | 10.1007/s00280-012-1941-8 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_journals_1069316849</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2769733551</sourcerecordid><originalsourceid>FETCH-LOGICAL-c402t-89a53d671189a498f17b9a1008cf2905e6b1c13cd29751c934b1b0e11de10fd83</originalsourceid><addsrcrecordid>eNp1kMFuGyEQhlGVKnHcPEAvFVLUI-0M4F04WlbaWIrUS3tescDajjC7gV0lfvti2W1yiYTECD7-YT5CPiN8Q4D6ewbgChggZ6glMvWBzFAKzkBJcUFmIKRkixrkFbnO-REAJApxSa44V5XUUs-IW9Jha7Kn6zXN4-QOtO-o660fzYsPdAhTptE7MwQz7iItayiFj2Omz7txS_cFzGM5sjT2keW9CYFZHwINU9xQa6L16RP52JmQ_c15n5M_P-5-r-7Zw6-f69XygVkJfGRKm4VwVY1YKqlVh3WrTZlU2Y5rWPiqRYvCOq7rBVotZIsteETnETqnxJzcnnKH1D9NPo_NYz-lWFo2CJUWWCmpC4UnyqY-5-S7Zki7vUmHAjVHr83Ja1O8NkevzTH5yzl5avfe_X_xT2QBvp4Bk60JXSqD7_IrV0lZYY2F4ycul6u48entF9_r_hccT47x</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1069316849</pqid></control><display><type>article</type><title>A phase II study of docetaxel plus nedaplatin in patients with metastatic non-small-cell lung cancer</title><source>MEDLINE</source><source>Springer Nature - Complete Springer Journals</source><creator>Teramoto, Koji ; Asada, Yoshikuni ; Ozaki, Yoshitomo ; Suzumura, Yuji ; Nakano, Yasutaka ; Sawai, Satoru ; Tezuka, Noriaki ; Inoue, Shuhei ; Fujino, Shozo</creator><creatorcontrib>Teramoto, Koji ; Asada, Yoshikuni ; Ozaki, Yoshitomo ; Suzumura, Yuji ; Nakano, Yasutaka ; Sawai, Satoru ; Tezuka, Noriaki ; Inoue, Shuhei ; Fujino, Shozo</creatorcontrib><description>Purpose
Nedaplatin is a cisplatin derivative, which has similar activity to cisplatin in non-small-cell lung cancer (NSCLC) when combined with vindesine, and causes less nausea/vomiting and nephrotoxicity compared with cisplatin. The aim of this study was to evaluate the efficacy and safety of combination chemotherapy with docetaxel plus nedaplatin in patients with metastatic NSCLC.
Methods
Patients with metastatic stage IIIB excluding locally advanced diseases or stage IV NSCLC were enrolled between March 2004 and March 2006. They were treated with docetaxel (60 mg/m
2
) and nedaplatin (80 mg/m
2
) on day 1 every 3–4 weeks until progression or intolerable toxicity for up to 4 cycles.
Results
Forty-four patients (mean age, 65 years; range, 40–79 years) received a total of 140 treatment cycles. Responses could be assessed in all patients (complete response, 0; partial response, 22; stable disease, 11; and progressive disease, 11). Response rate was 50.0 % (95 % confidence interval [CI], 35.2–64.8 %) with a disease control rate of 75.0 % (95 % CI, 62.2–87.8 %). A high response rate was achieved in patients with squamous cell carcinoma (66.7 %) compared with that in patients with adenocarcinoma (41.4 %). Median survival time from the start of the combination chemotherapy was 13.0 months, and the progression-free survival time was 7.4 months. Grade 3 or 4 hematologic toxicities included leukopenia (28.6 %) and neutropenia (61.4 %). Nonhematologic toxicities were mild.
Conclusion
The combination of docetaxel plus nedaplatin was well tolerated and demonstrated potent activity in patients with metastatic NSCLC, particularly squamous cell carcinoma of the lung.</description><identifier>ISSN: 0344-5704</identifier><identifier>EISSN: 1432-0843</identifier><identifier>DOI: 10.1007/s00280-012-1941-8</identifier><identifier>PMID: 22864949</identifier><identifier>CODEN: CCPHDZ</identifier><language>eng</language><publisher>Berlin/Heidelberg: Springer-Verlag</publisher><subject>Adult ; Aged ; Antineoplastic agents ; Antineoplastic Combined Chemotherapy Protocols - therapeutic use ; Biological and medical sciences ; Cancer Research ; Carcinoma, Non-Small-Cell Lung - drug therapy ; Carcinoma, Non-Small-Cell Lung - mortality ; Carcinoma, Non-Small-Cell Lung - pathology ; Dermatology ; Female ; Humans ; Lung cancer ; Lung Neoplasms - drug therapy ; Lung Neoplasms - mortality ; Lung Neoplasms - pathology ; Male ; Medical sciences ; Medicine ; Medicine & Public Health ; Middle Aged ; Neoplasm Staging ; Oncology ; Organoplatinum Compounds - administration & dosage ; Organoplatinum Compounds - adverse effects ; Original Article ; Pharmacology. Drug treatments ; Pharmacology/Toxicology ; Pneumology ; Taxoids - administration & dosage ; Taxoids - adverse effects ; Tumors of the respiratory system and mediastinum ; Tumors of the skin and soft tissue. Premalignant lesions</subject><ispartof>Cancer chemotherapy and pharmacology, 2012-10, Vol.70 (4), p.531-537</ispartof><rights>Springer-Verlag 2012</rights><rights>2015 INIST-CNRS</rights><rights>Springer-Verlag Berlin Heidelberg 2012</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c402t-89a53d671189a498f17b9a1008cf2905e6b1c13cd29751c934b1b0e11de10fd83</citedby><cites>FETCH-LOGICAL-c402t-89a53d671189a498f17b9a1008cf2905e6b1c13cd29751c934b1b0e11de10fd83</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s00280-012-1941-8$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1007/s00280-012-1941-8$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>314,776,780,27901,27902,41464,42533,51294</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=26446171$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/22864949$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Teramoto, Koji</creatorcontrib><creatorcontrib>Asada, Yoshikuni</creatorcontrib><creatorcontrib>Ozaki, Yoshitomo</creatorcontrib><creatorcontrib>Suzumura, Yuji</creatorcontrib><creatorcontrib>Nakano, Yasutaka</creatorcontrib><creatorcontrib>Sawai, Satoru</creatorcontrib><creatorcontrib>Tezuka, Noriaki</creatorcontrib><creatorcontrib>Inoue, Shuhei</creatorcontrib><creatorcontrib>Fujino, Shozo</creatorcontrib><title>A phase II study of docetaxel plus nedaplatin in patients with metastatic non-small-cell lung cancer</title><title>Cancer chemotherapy and pharmacology</title><addtitle>Cancer Chemother Pharmacol</addtitle><addtitle>Cancer Chemother Pharmacol</addtitle><description>Purpose
Nedaplatin is a cisplatin derivative, which has similar activity to cisplatin in non-small-cell lung cancer (NSCLC) when combined with vindesine, and causes less nausea/vomiting and nephrotoxicity compared with cisplatin. The aim of this study was to evaluate the efficacy and safety of combination chemotherapy with docetaxel plus nedaplatin in patients with metastatic NSCLC.
Methods
Patients with metastatic stage IIIB excluding locally advanced diseases or stage IV NSCLC were enrolled between March 2004 and March 2006. They were treated with docetaxel (60 mg/m
2
) and nedaplatin (80 mg/m
2
) on day 1 every 3–4 weeks until progression or intolerable toxicity for up to 4 cycles.
Results
Forty-four patients (mean age, 65 years; range, 40–79 years) received a total of 140 treatment cycles. Responses could be assessed in all patients (complete response, 0; partial response, 22; stable disease, 11; and progressive disease, 11). Response rate was 50.0 % (95 % confidence interval [CI], 35.2–64.8 %) with a disease control rate of 75.0 % (95 % CI, 62.2–87.8 %). A high response rate was achieved in patients with squamous cell carcinoma (66.7 %) compared with that in patients with adenocarcinoma (41.4 %). Median survival time from the start of the combination chemotherapy was 13.0 months, and the progression-free survival time was 7.4 months. Grade 3 or 4 hematologic toxicities included leukopenia (28.6 %) and neutropenia (61.4 %). Nonhematologic toxicities were mild.
Conclusion
The combination of docetaxel plus nedaplatin was well tolerated and demonstrated potent activity in patients with metastatic NSCLC, particularly squamous cell carcinoma of the lung.</description><subject>Adult</subject><subject>Aged</subject><subject>Antineoplastic agents</subject><subject>Antineoplastic Combined Chemotherapy Protocols - therapeutic use</subject><subject>Biological and medical sciences</subject><subject>Cancer Research</subject><subject>Carcinoma, Non-Small-Cell Lung - drug therapy</subject><subject>Carcinoma, Non-Small-Cell Lung - mortality</subject><subject>Carcinoma, Non-Small-Cell Lung - pathology</subject><subject>Dermatology</subject><subject>Female</subject><subject>Humans</subject><subject>Lung cancer</subject><subject>Lung Neoplasms - drug therapy</subject><subject>Lung Neoplasms - mortality</subject><subject>Lung Neoplasms - pathology</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Middle Aged</subject><subject>Neoplasm Staging</subject><subject>Oncology</subject><subject>Organoplatinum Compounds - administration & dosage</subject><subject>Organoplatinum Compounds - adverse effects</subject><subject>Original Article</subject><subject>Pharmacology. Drug treatments</subject><subject>Pharmacology/Toxicology</subject><subject>Pneumology</subject><subject>Taxoids - administration & dosage</subject><subject>Taxoids - adverse effects</subject><subject>Tumors of the respiratory system and mediastinum</subject><subject>Tumors of the skin and soft tissue. Premalignant lesions</subject><issn>0344-5704</issn><issn>1432-0843</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2012</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>BENPR</sourceid><recordid>eNp1kMFuGyEQhlGVKnHcPEAvFVLUI-0M4F04WlbaWIrUS3tescDajjC7gV0lfvti2W1yiYTECD7-YT5CPiN8Q4D6ewbgChggZ6glMvWBzFAKzkBJcUFmIKRkixrkFbnO-REAJApxSa44V5XUUs-IW9Jha7Kn6zXN4-QOtO-o660fzYsPdAhTptE7MwQz7iItayiFj2Omz7txS_cFzGM5sjT2keW9CYFZHwINU9xQa6L16RP52JmQ_c15n5M_P-5-r-7Zw6-f69XygVkJfGRKm4VwVY1YKqlVh3WrTZlU2Y5rWPiqRYvCOq7rBVotZIsteETnETqnxJzcnnKH1D9NPo_NYz-lWFo2CJUWWCmpC4UnyqY-5-S7Zki7vUmHAjVHr83Ja1O8NkevzTH5yzl5avfe_X_xT2QBvp4Bk60JXSqD7_IrV0lZYY2F4ycul6u48entF9_r_hccT47x</recordid><startdate>20121001</startdate><enddate>20121001</enddate><creator>Teramoto, Koji</creator><creator>Asada, Yoshikuni</creator><creator>Ozaki, Yoshitomo</creator><creator>Suzumura, Yuji</creator><creator>Nakano, Yasutaka</creator><creator>Sawai, Satoru</creator><creator>Tezuka, Noriaki</creator><creator>Inoue, Shuhei</creator><creator>Fujino, Shozo</creator><general>Springer-Verlag</general><general>Springer</general><general>Springer Nature B.V</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7TO</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8C1</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>H94</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope></search><sort><creationdate>20121001</creationdate><title>A phase II study of docetaxel plus nedaplatin in patients with metastatic non-small-cell lung cancer</title><author>Teramoto, Koji ; Asada, Yoshikuni ; Ozaki, Yoshitomo ; Suzumura, Yuji ; Nakano, Yasutaka ; Sawai, Satoru ; Tezuka, Noriaki ; Inoue, Shuhei ; Fujino, Shozo</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c402t-89a53d671189a498f17b9a1008cf2905e6b1c13cd29751c934b1b0e11de10fd83</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2012</creationdate><topic>Adult</topic><topic>Aged</topic><topic>Antineoplastic agents</topic><topic>Antineoplastic Combined Chemotherapy Protocols - therapeutic use</topic><topic>Biological and medical sciences</topic><topic>Cancer Research</topic><topic>Carcinoma, Non-Small-Cell Lung - drug therapy</topic><topic>Carcinoma, Non-Small-Cell Lung - mortality</topic><topic>Carcinoma, Non-Small-Cell Lung - pathology</topic><topic>Dermatology</topic><topic>Female</topic><topic>Humans</topic><topic>Lung cancer</topic><topic>Lung Neoplasms - drug therapy</topic><topic>Lung Neoplasms - mortality</topic><topic>Lung Neoplasms - pathology</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Middle Aged</topic><topic>Neoplasm Staging</topic><topic>Oncology</topic><topic>Organoplatinum Compounds - administration & dosage</topic><topic>Organoplatinum Compounds - adverse effects</topic><topic>Original Article</topic><topic>Pharmacology. Drug treatments</topic><topic>Pharmacology/Toxicology</topic><topic>Pneumology</topic><topic>Taxoids - administration & dosage</topic><topic>Taxoids - adverse effects</topic><topic>Tumors of the respiratory system and mediastinum</topic><topic>Tumors of the skin and soft tissue. Premalignant lesions</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Teramoto, Koji</creatorcontrib><creatorcontrib>Asada, Yoshikuni</creatorcontrib><creatorcontrib>Ozaki, Yoshitomo</creatorcontrib><creatorcontrib>Suzumura, Yuji</creatorcontrib><creatorcontrib>Nakano, Yasutaka</creatorcontrib><creatorcontrib>Sawai, Satoru</creatorcontrib><creatorcontrib>Tezuka, Noriaki</creatorcontrib><creatorcontrib>Inoue, Shuhei</creatorcontrib><creatorcontrib>Fujino, Shozo</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>ProQuest Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>ProQuest Public Health Database</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central UK/Ireland</collection><collection>AUTh Library subscriptions: ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><jtitle>Cancer chemotherapy and pharmacology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Teramoto, Koji</au><au>Asada, Yoshikuni</au><au>Ozaki, Yoshitomo</au><au>Suzumura, Yuji</au><au>Nakano, Yasutaka</au><au>Sawai, Satoru</au><au>Tezuka, Noriaki</au><au>Inoue, Shuhei</au><au>Fujino, Shozo</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>A phase II study of docetaxel plus nedaplatin in patients with metastatic non-small-cell lung cancer</atitle><jtitle>Cancer chemotherapy and pharmacology</jtitle><stitle>Cancer Chemother Pharmacol</stitle><addtitle>Cancer Chemother Pharmacol</addtitle><date>2012-10-01</date><risdate>2012</risdate><volume>70</volume><issue>4</issue><spage>531</spage><epage>537</epage><pages>531-537</pages><issn>0344-5704</issn><eissn>1432-0843</eissn><coden>CCPHDZ</coden><abstract>Purpose
Nedaplatin is a cisplatin derivative, which has similar activity to cisplatin in non-small-cell lung cancer (NSCLC) when combined with vindesine, and causes less nausea/vomiting and nephrotoxicity compared with cisplatin. The aim of this study was to evaluate the efficacy and safety of combination chemotherapy with docetaxel plus nedaplatin in patients with metastatic NSCLC.
Methods
Patients with metastatic stage IIIB excluding locally advanced diseases or stage IV NSCLC were enrolled between March 2004 and March 2006. They were treated with docetaxel (60 mg/m
2
) and nedaplatin (80 mg/m
2
) on day 1 every 3–4 weeks until progression or intolerable toxicity for up to 4 cycles.
Results
Forty-four patients (mean age, 65 years; range, 40–79 years) received a total of 140 treatment cycles. Responses could be assessed in all patients (complete response, 0; partial response, 22; stable disease, 11; and progressive disease, 11). Response rate was 50.0 % (95 % confidence interval [CI], 35.2–64.8 %) with a disease control rate of 75.0 % (95 % CI, 62.2–87.8 %). A high response rate was achieved in patients with squamous cell carcinoma (66.7 %) compared with that in patients with adenocarcinoma (41.4 %). Median survival time from the start of the combination chemotherapy was 13.0 months, and the progression-free survival time was 7.4 months. Grade 3 or 4 hematologic toxicities included leukopenia (28.6 %) and neutropenia (61.4 %). Nonhematologic toxicities were mild.
Conclusion
The combination of docetaxel plus nedaplatin was well tolerated and demonstrated potent activity in patients with metastatic NSCLC, particularly squamous cell carcinoma of the lung.</abstract><cop>Berlin/Heidelberg</cop><pub>Springer-Verlag</pub><pmid>22864949</pmid><doi>10.1007/s00280-012-1941-8</doi><tpages>7</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0344-5704 |
| ispartof | Cancer chemotherapy and pharmacology, 2012-10, Vol.70 (4), p.531-537 |
| issn | 0344-5704 1432-0843 |
| language | eng |
| recordid | cdi_proquest_journals_1069316849 |
| source | MEDLINE; Springer Nature - Complete Springer Journals |
| subjects | Adult Aged Antineoplastic agents Antineoplastic Combined Chemotherapy Protocols - therapeutic use Biological and medical sciences Cancer Research Carcinoma, Non-Small-Cell Lung - drug therapy Carcinoma, Non-Small-Cell Lung - mortality Carcinoma, Non-Small-Cell Lung - pathology Dermatology Female Humans Lung cancer Lung Neoplasms - drug therapy Lung Neoplasms - mortality Lung Neoplasms - pathology Male Medical sciences Medicine Medicine & Public Health Middle Aged Neoplasm Staging Oncology Organoplatinum Compounds - administration & dosage Organoplatinum Compounds - adverse effects Original Article Pharmacology. Drug treatments Pharmacology/Toxicology Pneumology Taxoids - administration & dosage Taxoids - adverse effects Tumors of the respiratory system and mediastinum Tumors of the skin and soft tissue. Premalignant lesions |
| title | A phase II study of docetaxel plus nedaplatin in patients with metastatic non-small-cell lung cancer |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-07T15%3A10%3A44IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=A%20phase%20II%20study%20of%20docetaxel%20plus%20nedaplatin%20in%20patients%20with%20metastatic%20non-small-cell%20lung%20cancer&rft.jtitle=Cancer%20chemotherapy%20and%20pharmacology&rft.au=Teramoto,%20Koji&rft.date=2012-10-01&rft.volume=70&rft.issue=4&rft.spage=531&rft.epage=537&rft.pages=531-537&rft.issn=0344-5704&rft.eissn=1432-0843&rft.coden=CCPHDZ&rft_id=info:doi/10.1007/s00280-012-1941-8&rft_dat=%3Cproquest_cross%3E2769733551%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1069316849&rft_id=info:pmid/22864949&rfr_iscdi=true |